Ascendis jumps as it inks R410m deal to sell pharma unit
Sale to lenders is necessary to avoid ratcheting up debt payments, and the figure is R35m higher than a competing offer
19 July 2022 - 09:41
UPDATED 19 July 2022 - 13:34
Shares of Ascendis Health were on track for their best day in seven months on Tuesday, after reaching terms on a R410m sale of its pharmaceutical business to its latest financier, Austell, one of two competing offers on the table.
The sale, still to be approved by shareholders, is necessary to avoid a ratcheting up of debt payments, and follows months of uncertainty for a group that has seen multiple board shake-ups and new lenders...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.